Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.
2024
Targeted induction before immunotherapy shows limited benefit in advanced melanoma
CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.
Neoadjuvant immunotherapy ‘the new standard’ for resectable stage III melanoma
CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.
Intralesional Therapy for Melanoma Effective, May Have Systemic Activity
CHICAGO — Preoperative intralesional treatment with a dual antibody-cytokine fusion significantly improved relapse-free survival (RFS) in locally advanced melanoma versus surgery alone, a randomized trial showed.